Search

The Axencia Galega de Innovación (Gain) has begun drafting the new Biotechnology Excellence Strategy 2026-2030 in Galicia with a survey aimed at professionals in the sector. The objective is to

The UTE BBZS_CAR-T consortium is advancing the CART_Andalucía project with a modular and scalable platform aimed at enabling more sustainable and effective access to advanced therapies.

These studies have provided new, robust data to assist decision-makers in resource allocation and have offered deep insights into the disease burden on the Spanish National Health System and the

For the biotechnology sector, it represents both a challenge and an opportunity, as it requires improved information management and the adoption of circular practices that promote more sustainable

The aim of this alliance is to promote social awareness of human papillomavirus, the most common sexually transmitted infection that can cause various types of cancer, including cervical cancer.

Essential thrombocythemia is the most common type of myeloproliferative neoplasm (MPN) and is associated with an increased risk of serious complications such as stroke, heart attack, and pulmonary

Digital twins make it possible to simulate personalised clinical scenarios without intervening directly on the patient, reducing uncertainty in decision-making.

Oryzon Genomics will be attending Bio-Neuroscience 2026, SmallCap Event 20th Edition, BIO-Europe Spring 2026 and LSX World Congress Europe.

The investment round was led by investment fund manager Heran Partners, with participation from Clave Capital, Inveready, and Bio&Tech Smart Capital.

Meet Medhionine, our new member. We spoke with Carmen Jiménez Medina, CEO.

These awards recognize scientific excellence in the field of natural products and their applications for health and well-being

We consider these appointments to be key to driving this historic process forward, as it will establish the rules governing European biotechnological innovation over the next two decades and lay the

The incorporation of advanced biotechnological assets—such as proteins, peptides, fermented products, or cell derivatives—adds the challenge of ensuring their robust and reliable manufacture, scaling

Don’t miss the opportunity to secure the best exhibition spaces, explore sponsorship options for maximum visibility, and register to attend one of Europe’s key industry gatherings, offering unique